Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trialAxel Bauer, Uwe Dorwarth, Michael Schreinlechner et al.|The Lancet Respiratory Medicine|2021Cited by 104
Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery DiseaseJohanna F. Schachtl‐Riess, Vera Krane, Sebastian Schoenherr et al.|Journal of the American College of Cardiology|2021Cited by 86